To provide insights into the role of multiparametric magnetic resonance imaging (mpMRI) in predicting oncological control following 2 focal ablation (FA) templates for selective cases of prostate cancer.
Materials and Methods
A total of 59 radical prostatectomies were performed between 2012 and 2016 on cases that fulfilled criteria for FA. The Gleason score (GS), extent of Gleason pattern (GP) 4, maximum linear cross-sectional length (MLCSL), and location of tumor foci were recorded and related to scale on corresponding 3-mm transverse slice prostate maps. Gleason pattern 4 extra-focal disease (GP4EFD) was defined as prostate cancer with any GP 4 not detected by mpMRI and transrectal ultrasound systematic biopsy observed outside a specified ablation zone. The location of these GP4EFD relative to the MRI lesion (MRI-L) (contralateral or ipsilateral) was recorded and used to predict oncological control following a hypothetical margin and ipsilateral hemi-ablation templates.
Overall, 15 of 59 (25.4%) of the prostate specimens had at least 1 GP4EFD. Of the total 20 GP4EFD, 7 of 20 (35%) were ipsilateral and 13 of 20 (65%) were contralateral to the MRI-L. Of the GP4EFD, 16 of 20 (80%), 2 of 20 (10%), and 2 of 20 (10%) were GS 3 + 4, GS 4 + 3, and GS 4 + 4, respectively. Of these GP4EFD, 10 of 20 (50%) exhibited an MLCSL <5 mm. Ablating only the MRI-L+10 mm or performing an ipsilateral hemi-ablation would leave residual GP4 in 14 of 59 (23.7%) and 11 of 59 (18.6%) of cases, respectively.
Because a significant proportion of candidates for FA based on mpMRI and systematic biopsy will have pre-existing GP4EFD outside ablation templates, active surveillance of the untreated prostate is mandatory.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Urology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- EAU guidelines on penile cancer: 2014 update.Eur Urol. 2015; 67: 142-150
- Guideline for management of the clinical T1 renal mass.J Urol. 2009; 182: 1271-1279
- Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline.J Urol. 2016; 196: 1021-1029
- European Association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update.Eur Urol. 2015; 68: 868-879
- Re-evaluating the concept of “dominant/index tumor nodule” in multifocal prostate cancer.Virchows Arch. 2014; 464: 589-594
- Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.Cancer. 2007; 110: 906-910
- Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen.J Urol. 1999; 162 (discussion 1357-1358.8): 1352-1357
- Analysis of apical soft tissue margins during radical retropubic prostatectomy.J Urol. 2001; 165 (discussion 1948-1949): 1943-1948
- Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard.Radiology. 2013; 268: 761-769
- Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study.Eur Radiol. 2013; 23: 2019-2029
- Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.JAMA. 2015; 313: 390-397
- Has magnetic resonance-guided biopsy of the prostate become the standard of care?.Eur Urol. 2013; 64: 720-721
- Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer.Surg Oncol. 2009; 18: 219-232
- Clinicaly localized prostate cancer: AUA/ASTRO/SUO guideline.(Available at:)http://www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-(aua/astro/suo-guideline-2017)Date: 2017Date accessed: August 10, 2017
- Focal therapy: patients, interventions, and outcomes—a report from a consensus meeting.Eur Urol. 2015; 67: 771-777
- Prostate cancer: multiparametric MRI for index lesion localization—a multiple-reader study.AJR Am J Roentgenol. 2012; 199: 830-837
- Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens.Urology. 2009; 74: 1094-1099
- Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.J Urol. 2006; 176: 2432-2437
- Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.J Urol. 2008; 180: 554-558
- Medium-term outcomes after whole-gland high-intensity focused ultrasound for the treatment of nonmetastatic prostate cancer from a multicentre registry cohort.Eur Urol. 2016; 70: 668-674
- Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer.BJU Int. 2013; 112: 322-329
- Salvage laparoscopic radical prostatectomy following high-intensity focused ultrasound for treatment of prostate cancer.Urology. 2012; 80: 130-133
- New and established technology in focal ablation of the prostate: a systematic review.Eur Urol. 2017; 71: 17-34
- Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study.Eur Urol. 2015; 68: 927-936
- Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology.Eur Urol. 2015; 67: 569-576
- Oncologic outcomes at 10 years following robotic radical prostatectomy.Eur Urol. 2015; 67: 1168-1176
- Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy.Urology. 2010; 76: 689-692
- Image guided focal therapy for magnetic resonance imaging visible prostate cancer: defining a 3-dimensional treatment margin based on magnetic resonance imaging histology co-registration analysis.J Urol. 2015; 194: 364-370
Published online: October 20, 2017
Accepted: October 10, 2017
Received: August 15, 2017
Financial Disclosure: The authors declare that they have no relevant financial interests.
© 2017 Elsevier Inc. All rights reserved.